Biotechnology firms are deploying natural language processing models to parse electronic health records, streamlining the identification of eligible candidates for clinical trials. The approach addresses historical delays in oncology and rare disease trial enrollment.
Data Privacy and Regulatory Alignment
Integrating predictive algorithms into trial design requires strict adherence to patient privacy mandates. Regulatory agencies have established preliminary guidelines to ensure algorithmic transparency and prevent demographic bias in study selection.